3685-62-9

Usage

Explanation

The compound's full name, which describes its structure and functional groups.

Explanation

The molecular formula representing the number of carbon (C), hydrogen (H), nitrogen (N), and oxygen (O) atoms in the compound.

Explanation

The compound is derived from a pyrimidine ring and has a propenyl group attached to the first carbon atom.

Explanation

It contains a cyclic amide group, which classifies it as a lactam.

Explanation

The compound is used as a starting material or intermediate in the synthesis of more complex organic molecules, particularly in the pharmaceutical industry.

Explanation

Due to its versatile structure, it can be used in the development of various chemical products, including pharmaceuticals, agricultural chemicals, and specialty chemicals.

Explanation

The properties of 1-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione, such as solubility, reactivity, and stability, can vary depending on the conditions and reactions it is involved in.

Explanation

The material does not provide information about the presence or absence of stereoisomers for 1-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione.

Explanation

The material does not provide specific information about the reactivity of the compound, which would depend on the functional groups present and the reaction conditions.

Structure

Pyrimidine derivative with a propenyl substituent at the 1-position

Type of Compound

Lactam

Applications

Building block in organic synthesis and pharmaceutical research

Potential Uses

Production of drugs, agrochemicals, and other fine chemicals

Specific Properties

Depend on the specific context and reactions

Stereoisomers

Not mentioned in the material

Reactivity

Not specified in the material

Upstream product

• 557-11-9 allylurea 
• 105-53-3 diethyl malonate 
• 623-76-7 N,N'-diethylurea 
• 141-82-2 malonic acid 
• 108-59-8 malonic acid dimethyl ester 

Downstream Products

• 552291-26-6 3-allyl-6-chloro-1-(2,6-difluoro-benzyl)-1H-pyrimidine-2,4-dione 
• 552291-27-7 3-allyl-1-(2,6-difluoro-benzyl)-6-ethyl-1H-pyrimidine-2,4-dione 
• 552291-28-8 [5-bromo-3-(2,6-difluoro-benzyl)-4-ethyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-acetaldehyde 
• 1027033-30-2 2-[1-allyl-3-(2,6-difluoro-benzyl)-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl]-2-methyl-malonic acid diethyl ester 

Relevant academic research and scientific papers

Antibacterial barbituric acid analogues inspired from natural 3-acyltetramic acids; Synthesis, tautomerism and structure and physicochemical property-antibacterial activity relationships

The synthesis, tautomerism and antibacterial activity of novel barbiturates is reported. In particular, 3-acyl and 3-carboxamidobarbiturates exhibited antibacterial activity, against susceptible and some resistant Gram-positive strains of particular inter

Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening

Despite the increasing need of new antituberculosis drugs, the number of agents approved for the market has fallen to an all-time low. In response to the emerging drug resistance followed, structurally unique chemical entities will be highlighted. decaprenylphosphoryl-β-D-ribose oxidase (DprE1) participating in the biosynthesis of mycobacterium cell wall is a highly vulnerable and validated antituberculosis target. On the basis of it, a systematic strategy was applied to identify a high-quality lead compound (compound 50) that inhibits the essential enzyme DprE1, thus blocking the synthesis of the mycobacterial cell wall to kill M. tuberculosis in vitro and in vivo. Correspondingly, the rational design and synthetic strategy for compound 50 was reported. Notably, the compound 50 has been confirmed to be no toxicity. Altogether, our data suggest the compound 50 targeting DprE1 is a promising candidate for the tuberculosis (TB) therapy.

SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF

The invention relates to substituted hydrazide compounds as shown by general formula I, including geometrical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and use of the same, wherein the substitutents Ar and R have the same meanings as given in the Description. The invention further relates to the use of compounds of general formula I in the preparation of medicament for the treatment and/or prevention of cancer and other proliferative diseases.

SUBSTITUTED HYDRAZIDE COMPOUNDS AND APPLICATION THEREOF

The invention relates to substituted hydrazide compounds as shown by general formula I, including geometrical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and use of the same, wherein the substitutents Ar and R having the same meanings as given in the Description. T The invention further relates to the use of compounds of general formula I in the preparation of medicament for the treatment and/or prevention of cancer and other proliferative diseases.

Identification of 1-arylmethyl-3-(2-aminoethyl)-5-aryluracil as novel gonadotropin-releasing hormone receptor antagonists

Based on SAR from bicyclic GnRH antagonists such as 6-aminomethyl-7-arylpyrrolo[1,2-a]pyrimid-4-ones (1) and 2-aryl-3-aminomethylimidazolo[1,2-a]pyrimid-5-ones (2a,b), a series of novel uracil compounds (4) were derived as the GnRH antagonists. Their synt